Background. The objective of this study was to evaluate the interaction between the length polymorphism of the guanosine thymidine repeat [(GT) n ] in the heme oxygenase-1 (HO-1) gene and far-infrared (FIR) therapy on access flow (Qa) and arteriovenous fistula (AVF) patency in hemodialysis (HD) patients. Results. The Qa decreased from S/S to S/L and further to the L/L group but increased by FIR therapy with the highest Qa increase in the S/S group. The incidence of AVF malfunction decreased both from the L/L, S/L to S/S group (32.4 versus 17.2 versus 10.9%, P = 0.007) and from the control group to FIR group (27.5 versus 12.6%, P = 0.004). Significant associations were found between AVF malfunction and the following factors
mechanical, medical or genetic factors. Individual differences in the genetic background may influence the susceptibility to vascular inflammation and neointimal formation following endothelial and smooth muscle injury. Consistent with this notion, AVF survival was reported to be associated with specific genetic polymorphisms of transforming growth factor β-1 [3] and methylene tetrahydrofolate reductase [4] . Interestingly, we found that a long guanosine thymidine dinucleotide repeat [(GT) n ≥ 30] in the HO-1 promoter, which is linked to impaired inducibility, is associated with a higher frequency of access failure and diminished patency of AVFs in HD patients [5] . HO-1 catalyzes the oxidative degradation of heme into equimolar amounts of biliverdin, free iron and carbon monoxide (CO) [6, 7] . Biliverdin is subsequently metabolized to bilirubin by the enzyme biliverdin reductase. Induction of HO-1 elicits potent anti-inflammatory, anti-proliferative, antithrombotic and anti-oxidant effects in the circulation via the generation of CO and bilirubin, suggesting a critical role for HO-1 in regulating the survival of AVFs [6] .
Far-infrared (FIR) radiation is an invisible electromagnetic wave with a defined wavelength between 5.6 and 1000 μm [8] . Recent studies indicate that FIR therapy may improve the prognosis of cardiovascular diseases [9, 10] . Moreover, FIR radiation increases microvascular blood flow and angiogenesis in animal models [11] . Interestingly, we recently demonstrated that FIR therapy improves access flow (Qa) and patency of AVFs in HD patients [12] .
Although very little information is available concerning the therapeutic mechanisms of FIR treatment, our recent study has demonstrated that the anti-inflammatory effect of FIR comes from the stimulation of the expression of heme oxygenase-1 (HO-1), leading to the inhibition of tumor necrosis factor-α (TNF-α)-induced expression of adhesion molecules in endothelial cells as well as in HD patients [13] . Thus, we hypothesized that the effect of FIR to improve access flow and patency of AVF may vary according to length polymorphisms of the HO-1 gene. Accordingly, this study was designed to determine whether there is a physicogenomic interaction, i.e. an interactive effect between physical therapy as FIR and the length polymorphism of the [(GT) n ] in the HO-1 gene promoter region on Qa and patency of AVF in HD patients.
M AT E R I A L S A N D M E T H O D S

Patient selection
In this study, we included patients who met the following criteria: (i) receiving 4 h of maintenance HD therapy three times weekly for at least 6 months at Taipei Veterans General Hospital, (ii) using a native AVF as the present vascular access for >6 months, without interventions within the last 3 months and (iii) creation of AVF by cardiovascular surgeons in our hospital with the standardized surgical procedures of venous end-to-arterial side anastomosis in the upper extremity. Patients were excluded if they received an AV graft as the first vascular access. The medical records and blood samples for genotyping were available from these patients.
This study is a prospective, randomized, controlled trial based on the Helsinki Declaration (edition 6, revised 2000). It was approved by the Institutional Research Board of Taipei Veterans General Hospital and was first registered at the Cochrane Renal Group registry (CRG050600078) in 2005 and then transferred to the Australian New Zealand Clinical Trials Registry (ACTRN12610000704099) in August 2010. After informed consent was obtained from every study subject, the patients were randomly allocated to receive FIR therapy for 12 months as the FIR group or not to receive infrared therapy as the control group in four randomization cycles, using computer-generated numbers. The randomized treatment assignments were sealed in opaque envelopes and were opened individually for each patient who agreed to be in the study. The sponsors had no role in the design and conduct of the study; the collection, management, analysis or interpretation of the data; or the preparation, review or approval of the manuscript. The allocation sequence was kept by two study nurses (Miss CF Hung and HT Cheng) who did not disclose the subject allocation to the investigator until the time of intervention. We conducted this study from May 2005 to December 2007. The primary end point was the survival time of the AVF with unassisted patency, which was defined as the time from the commencement of the study to the first episode of AVF malfunction. We defined AVF malfunction as the need for any interventional procedure (surgery or angioplasty) to correct an occlusive or malfunctioning fistula which could not sustain an extracorporeal blood flow >200 mL/min during HD after excluding the following stenosis-unrelated events, such as infectious complication, progressive aneurysmal formation or steal syndrome.
Determination of length polymorphism of (GT) n repeats in HO-1 gene promoter Peripheral blood without dietary control during voluntary HD was collected in a tube containing EDTA-2K and immediately subjected to genomic DNA extraction procedures. Genomic DNA was isolated using the Puregene DNA purification kit (Gentra, MN). The (GT) n repeat at the promoter region of the HO-1 gene was amplified by polymerase chain reaction (PCR) and determined according to a detailed protocol as shown in our previous study [5] . All fragment analyses contained appropriate negative and positive controls.
Measurement of access flow and cardiac output
The access flow (Qa) and cardiac output were measured during HD by ultrasound dilution method using the Transonic HD0 2 HD monitor (Transonic Systems, Inc., Ithaca, NY). The technique is widely used and the detailed steps of measurement were recorded in the literature [14] . All the data of Qa were measured twice and a third measurement was done if the difference between the first two data was >10%. The mean of the two closest values was recorded into our data base.
Far-infrared therapy
In this study, a WS TM TY101 FIR emitter (WS Far-Infrared Medical Technology Co., Ltd., Taipei, Taiwan) was used for
H O -1 a n d F I R o n A V F p a t e n c y FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak around 5-6 μm). The top radiator was set at a height of 25 cm above the surface of the AVF with the treatment time set at 40 min during HD three times a week.
Study protocol: the effect of 1 year of FIR therapy on access flow and unassisted patency of the AVF in HD patients Every hemodynamic parameter was measured at four different times for each patient by the time they had completed this study. In the control group, we defined Time 1 as the time point within the first 1 h of the HD session a week prior to the start of this study, Time 2 as the time point 40 min after time 1, Time 3 as the same time as time 1 but at the end of the study 1 year later and Time 4 as 40 min after time 3. In the treatment group, time 1 to time 4 were defined the same as those in the control group, except that 40 min of FIR therapy was given during HD three times a week for a year. Consequently, Qa 1 indicates access flow measured at Time 1, Qa 2 at Time 2, Qa 3 at Time 3 and Qa 4 at Time 4 [12] . During the 1-year follow-up, patients were censored because of renal transplantation, death with a functioning access, shifting to peritoneal dialysis or loss of follow-up.
Statistical analysis
All data were checked for normal distribution before statistical analysis. Continuous variables with normal distribution in two and three groups were expressed as mean ± SD and compared by Student's t-test and analysis of variance with Dunnett's post-hoc test, respectively. Nonparametric data in two and three groups were analyzed using the Mann-Whitney U and Kruskal-Wallis tests, respectively. Categorical variables, such as the distribution of genotype frequencies in patients and controls were analyzed by Chi-square test. The Cox regression model was performed to adjust for other established risk factors of AVF stenosis. Adjusted odds ratio and 95% confidence interval for every explanatory variable were also calculated. Survival curves of unassisted patency of AVF were calculated by the Kaplan-Meier method and compared by the log-rank test. A statistically significant value was P < 0.05. Data management and statistical analysis were performed using the SPSS version 17.0 statistical software (SPSS, Inc., Chicago, IL).
R E S U LT S
Patient characteristics
We enrolled a total of 280 patients in this study as shown in Figure 1 . Among these participants, 139 HD patients were randomly assigned to the FIR group and 141 HD patients were assigned as controls, but two refused to be allocated to the control group. As listed in Table 1 , there were no differences in the demographic and clinical characteristics between the two groups of HD patients. During the 1-year study period, three patients receiving FIR therapy and two patients in the control group underwent creation of another vascular access due to nonstenotic causes, including steal syndrome, and infectious or aneurysmal complications. Furthermore, patients were censored at the time of renal transplantation (n = 5) for death with a functioning access (n = 15), shift to peritoneal dialysis (n = 5) or loss of follow-up (n = 9). Finally, 239 patients completed the study with 119 patients in the FIR group and 120 patients in the control group.
The interactive effect between HO-1 length polymorphism and 1 year of FIR therapy on access flow and malfunction of AVF in HD patients As shown in Table 2 Cox regression model of multivariate analysis for AVF malfunction Table 3 shows the Cox regression model for the association of AVF malfunction with HO-1 genotype, FIR therapy and some selected variables which may affect the patency of AVF. There was no statistical significance for gender, history of diabetes mellitus or coronary artery disease, while there was only a borderline significance for duration of AVF (P = 0.052). However, a higher risk of AVF malfunction at 1 year was associated with age, number of dialysis procedure, AVF calcification either at the beginning or at the end of the study and history of previous AVF malfunction, whereas a lower risk of AVF malfunction is associated with wider diameter of the feeding artery of AVF. Even after the above-mentioned factors were adjusted, HO-1 length polymorphism was still a strong risk factor for AVF malfunction, with a hazard ratio of 2.016 for L/L genotype (versus S/S + S/L genotypes, P = 0.021) while 1-year FIR therapy remained effective in preventing AVF malfunction (hazard ratio of 0.576 versus control group, P = 0.034).
Access survival
During the follow-up period, AVF malfunction was observed in 15 patients in the FIR group and 33 patients in the
control group. Thus, the unassisted patency of AVF at 1 year was significantly better in the FIR group than in the control group (87.4 versus 72.5%; P = 0.003 by Log rank test) as shown in Figure 2A . In addition, AVF patency differed significantly when patients were classified according to their HO-1 genotypes. The unassisted patency of AVF at 1 year decreased significantly from 89.1% in patients with S/S genotypes to 82.8% in patients with S/L genotypes and further to 67.6% in patients with L/L genotypes (P = 0.005 by Log-rank test; Figure 2B ). In terms of the interactive effect between FIR therapy and length polymorphism of the HO-1 gene on AVF survival, the unassisted patency of AVF decreased significantly from 91.9% in patients with either S/S or S/L genotype of HO-1 gene and FIR therapy and to 77.6% in those with S/S or S/L genotype of HO-1 gene, but without FIR therapy; whereas it was 75.8% for patients with L/L genotype of HO-1 gene and FIR therapy and only 60% for those with L/L genotype of HO-1 gene but without FIR therapy (P < 0.001 by Log-rank test; Figure 2C ). Figure 2 , Figure 3 shows 5-year cumulative patency of AVF is significantly higher in HD patients with (i) FIR therapy (87.1 versus 78.7% for controls, P = 0.0499; Figure 3A ), (i) specific HO-1 genotypes (90.9% for S/ S > 83.8% for S/L > 74.4% for L/L genotype, P = 0.022; Figure 3B ) and (iii) specific combinations of specific HO-1 genotype and therapeutic status with or without FIR therapy (90.1% for S/S + S/L + FIR > 82.2% for S/S + S/L without FIR > 78.9% for L/L + FIR > 70.0% for L/L without FIR, P = 0.017; Figure 3C ). Concerning the safety issue of FIR therapy, no patient complained of any side effect, such as skin burn or allergy to the FIR therapy throughout the whole course of the study.
Similar to
D I S C U S S I O N
In this novel physicogenomic study (i.e. evaluating the influence of the genetic background on the clinical response to F I G U R E 1 : Flow chart of the study participants for the randomized, controlled trial to evaluate the interactive effect between far-infrared (FIR) therapy and HO-1 genotype on the survival of AVF in HD patients.
O R I G I N A L A R T I C L E
L I N ; H O -1 a n d F I R o n A V F p a t e n c y physical therapy), we showed that FIR therapy may improve access flow and unassisted patency in HD patients and the best protective effect was noticed in patients with S/S genotype of HO-1 gene. In the meanwhile, L/L genotype of HO-1 length polymorphism was found to be associated with lower patency of AVF and poorer response to FIR therapy in HD patients.
We defined GT repeats ≥30 as long (class L) allele and GT repeats <30 as short (class S) allele according to the classification by Yamada et al. [15] in a Japanese population (who are Asians, as were our patients). At the cellular level, a longer (GT) n repeat number in the promoter region of HO-1 gene was associated with a lower transcriptional activity [16] . Recently, emerging evidence has shown that a longer (GT) n repeat in the promoter region of the HO-1 gene is associated with some human vascular diseases [15] [16] [17] . The effect of HO-1 gene length polymorphism on AVF patency of HD patients without FIR therapy could be explained by the following mechanisms. The longer dinucleotide GT repeat in the promoter region was associated with a lower HO-1 gene transcription. HO-1 catalyzes the synthesis of bilirubin and carbon monoxide (CO), which are responsible for potent anti-inflammatory, anti-proliferative, anti-thrombotic and anti-oxidant effects [6, 7] . Consequently, a longer length polymorphism of the HO-1 gene may offset the protective effect (through CO and bilirubin) against vascular injury, leading to a higher frequency of access failure and diminished patency of AVFs in HD patients, which was confirmed by our previous study [5] .
Infrared radiation can be divided into three categories according to wavelength, including near-infrared radiation 
H O -1 a n d F I R o n A V F p a t e n c y (0.75-1.5 μm), middle-infrared radiation (1.5-5.6 μm) and FIR radiation (5.6-1000 μm). FIR was demonstrated to improve skin blood flow and to reduce the frequency of some cardiovascular diseases in both animal and clinical studies [9, 11] . In addition, we have shown in our previous study that 40 min of FIR therapy in a single HD session could increase Qa of AVF by about 50 mL/min with a 1-year effect of improving Qa by up to 150 mL/min and increasing unassisted patency of AVF by about 18% in comparison with controls [12] . These results support the notion that both the thermal and nonthermal effects of FIR can increase the access flow. Vasodilatation caused by the thermal effect of FIR can increase the access flow of AVF on account of multiple energy transfers as deep as 2 to 3 cm into subcutaneous tissue [18] . However, the skin temperature was only increased up to 38 ∼ 39°C after 30-60 min of FIR treatment as long as the distance between the ceramic plate and the skin was >20 cm. Therefore, FIR therapy can help to avoid the adverse effects of Values are expressed as the mean ± SD. Qa 1 indicates the access flow measured within first hour after the initiation of the HD session 1 week prior to the commencement of this study. some traditional methods of thermal therapy, including burn injury, infection and risk of access failure due to prolonged compression, etc. Other than the above-mentioned thermal effect, four possible mechanisms may explain the nonthermal effects of infrared therapy, including (i) inhibition of intimal hyperplasia, (ii) decrease of oxidative stress, (iii) suppression of inflammation and (iv) improvement of endothelial function. With regard to the effect of FIR on neointimal hyperplasia inhibition, nonablative infrared laser (NIL) therapy was shown to slow the growth of vascular smooth muscle cells (VSMC) after PTCA in cholesterol-fed rabbits [19] . In terms of the effect on oxidative stress, patients receiving 45 min of FIR dry sauna daily for 2 weeks had significantly lower urinary levels of 8-epiprostaglandin F2α (a marker of oxidative stress in vivo) than the control group [20] . Our recent study also showed that the anti-inflammatory effect of FIR comes from the stimulation of the expression of HO-1 via NF-E2-related factor-2 (Nrf2)-dependent promoter activity, leading to the inhibition of tumor necrosis factor-α (TNF-α) induced expression of adhesion molecules in endothelial cells as well as in HD patients [13] . The endothelial function-improving effect of FIR was also observed in a clinical study for patients with coronary risk factors [9] as well as animal studies focusing on skin blood flow [11] , angiogenesis in unilateral hind limb ischemia [21] and the expression of eNOS in the aortas [22] . Since the patency of AVF is associated with HO-1 genotype polymorphism and the administration of FIR therapy, we also analyzed the effect of FIR on the change of access flow in HD patients with different genotypes of HO-1. We demonstrated that there was an additive benefit of both the thermal and nonthermal effects, as indicated by Δ(Qa 4 − Qa 2 ), which was the item with the greatest difference among all of the above-mentioned incremental Qa, not only for all participants, but also for each group of specific HO-1 genotype. The absolute difference in the Qa-improving effect for Δ(Qa 4 − Qa 2 ) between those with and without FIR therapy was highest for S/S group, intermediate for S/L group and lowest for L/L group (196.1 ± 173.0 versus 130.0 ± 165.1 versus 125.6 ± 146.7 mL/min, P < 0.01). Thus, we demonstrated that FIR therapy improved access flow in HD patients and the best incremental effect was noticed in patients with S/S genotype of HO-1 gene, followed by those with S/L and L/L genotype, respectively. The long-term nonthermal effect, represented by Δ(Qa 3 − Qa 1 ), is also most obvious in the S/S group and accounts for 74.9% (146.9/196.1) of the total effect of FIR, which is higher than 60.2% (78.3/130) for the S/L group and 27.6% (34.7/125.6) for the L/L group. The higher proportion of totally FIR-increased access flow, contributed by nonthermal effects, in S/S group may be explained by the higher accumulation of FIR-induced HO-1 expression. This finding may be explained by the fact that patients with the S/S genotype have a higher activity of HO-1, leading to higher production of carbon monoxide and bilirubin, which is associated with higher anti-proliferative effect in vascular smooth muscle cells and anti-inflammatory effect in endothelial cells.
We acknowledge that some limitations should be considered in the interpretation of these study results. First, all our study subjects are Chinese living in Taiwan, so the characteristic of distinct ethnicity may limit the applicability of this study result to other ethnic groups. Second, the result should not be extrapolated to HD patients using AV graft as their vascular access because we only included patients with AVF. Third, this study was carried out in HD patients with pre-existing AVF rather than in patients with a new AVF. Even though we tried to control as many factors as we possibly could during randomization, a wide variation of vascular conditions among these individuals may still have influenced the final result.
In conclusion, we demonstrated the novel physico-genomic interactive effect that FIR therapy, a convenient and noninvasive technology, improves access flow and unassisted patency to different degrees in HD patients with specific length polymorphisms of the HO-1 gene. Particularly, the best protective effect by FIR therapy was noticed in patients with the S/S genotype of HO-1 gene.
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